Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Harrington

Showing results (71-80 of 197) with videos related to

Pageof 20
Sort By:
Cancers|June 26, 2026
Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway ActivationKaran Patel, Joseph Edward Haigh, Samuel Rack, et al.
British Journal of Cancer|October 21, 2015
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanomaAnna Wilkins, Andrew Furness, Richard W Corbett, et al.
Nature Biotechnology|June 10, 2003
A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilizationAtique Ahmed, Jill Thompson, Lisa Emiliusen, et al.
Molecular Cancer|February 23, 2011
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingLynette Steele, Fiona Errington, Robin Prestwich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapyFiona Errington, Andrew Bateman, Tim Kottke, et al.
Human Gene Therapy|August 7, 2002
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?Kevin Harrington, Luis Alvarez-Vallina, Marka Crittenden, et al.
Plos One|March 18, 2015
Brain-sparing methods for IMRT of head and neck cancerAlex Dunlop, Liam Welsh, Dualta McQuaid, et al.
Cancer Research|August 19, 2007
Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neckSutima Luangdilok, Carol Box, Lisa Patterson, et al.
Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideCandice Willmon, Rosa M Diaz, Phonphimon Wongthida, et al.
Pageof 20

Showing results (71-80 of 197) with videos related to

Sort By:
Pageof 20
Cancers|June 26, 2026
Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway ActivationKaran Patel, Joseph Edward Haigh, Samuel Rack, et al.
British Journal of Cancer|October 21, 2015
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanomaAnna Wilkins, Andrew Furness, Richard W Corbett, et al.
Nature Biotechnology|June 10, 2003
A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilizationAtique Ahmed, Jill Thompson, Lisa Emiliusen, et al.
Molecular Cancer|February 23, 2011
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingLynette Steele, Fiona Errington, Robin Prestwich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapyFiona Errington, Andrew Bateman, Tim Kottke, et al.
Human Gene Therapy|August 7, 2002
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?Kevin Harrington, Luis Alvarez-Vallina, Marka Crittenden, et al.
Plos One|March 18, 2015
Brain-sparing methods for IMRT of head and neck cancerAlex Dunlop, Liam Welsh, Dualta McQuaid, et al.
Cancer Research|August 19, 2007
Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neckSutima Luangdilok, Carol Box, Lisa Patterson, et al.
Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideCandice Willmon, Rosa M Diaz, Phonphimon Wongthida, et al.
Pageof 20